Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial
Alexander M.M. Eggermont(University Medical Center Utrecht), Alessandro Testori(European Organisation for Research and Treatment of Cancer), Michele Maio(University of Siena), Célèste Lebbé(Inserm), Omid Hamid(Cedars-Sinai Medical Center), Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Vanna Chiarion‐Sileni(Centre Hospitalier Universitaire Brugmann), Virginia Ferraresi(Cancer Institute (WIA)), Michal Kiciński(European Organisation for Research and Treatment of Cancer), Jeffrey S. Weber(NYU Langone Health), Jedd D. Wolchok(Cornell University), Veerle de Pril(Inserm), Henrik Schmidt(Aarhus University Hospital), Stefan Suciu(St James's University Hospital), Jon Richards(Oncology Specialists), Reinhard Dummer(University Hospital of Zurich), Caroline Robert(Institut Gustave Roussy), Fareeda Hosein(Bristol-Myers Squibb (United States)), Jean-Jacques Grob(Aix-Marseille Université), Michael Smylie(Inserm)
Cited by 181
Related Papers
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k